We performed rare variant genetic burden testing in a cohort of 578 PAH cases compared with 361 675 controls to determine whether patients with PAH carried an excess of LOF mutations within ATF4 or any of the enzymes under its control (Table 3). This evidence concerns the gene ATF4 and pulmonary arterial hypertension.